Syneron Announces the Launch of elure(TM) Advanced Skin Whitening Technology
in Singapore

    


    
</pre>
<p>YOKNEAM, <span class="xn-location">Israel</span>, <span class="xn-chron">Nov. 8, 2010</span> /CNW/ -- Today Syneron Medical Ltd. (Nasdaq: ELOS), <a href="http://www.syneron.com">http://www.syneron.com</a>, announces the initial commercial launch in <span class="xn-location">Singapore</span> of elure(TM) Advanced Skin Whitening Technology, the first and only skin lightening product that works by directly breaking down melanin - the molecule that accumulates in the skin to cause a darkened appearance. This novel targeted mechanism of action found only in elure provides the pathway for a meaningful improvement in the skin's tone, texture and radiance in as little as seven days.  More than this, elure lightens the skin without the commonly reported side effects of traditional skin lightening products, such as skin irritation. "elure is a much anticipated breakthrough in skin lightening," said Vivian W. Bucay, MD, US dermatologist and renowned skincare expert.  "Now my patients and their friends can experience very visible results in just a matter of days."</p>
<p/>
<p>The organically-based active ingredient of elure was developed after almost 30 years of research on a naturally occurring enzyme. "Lignin peroxidase, the active ingredient of elure, is a natural enzyme derived from a mushroom that grows on trees called Phanerochaete chrysosporium," said Yoram Karmon, PhD, one of the pioneer researchers of elure that also included Paula Belinky, MD, from Migal Galilee Technological Center in Kiryat Shmona, and Carlos Dosoretz, PhD, from the Technion-Israel Institute of Technology in <span class="xn-location">Haifa</span>. "Our research confirmed that lignin peroxidase uniquely breaks down or depolymerizes melanin in human skin."</p>
<p/>
<p>In clinical trials using elure, Alain Khaiat, PhD, President of the Cosmetic Toiletries and Fragrance Association of <span class="xn-location">Singapore</span> and a 30-year veteran in skincare product development, noted, "The safety and tolerability of elure is unparalleled. We tested the product at 17,000 times the recommended human dose and saw no potential for adverse events." Shimon Eckhouse, MD, Chairman and co-founder of Syneron commented, "The first commercial launch of elure in Asia marks an extremely important milestone for Syneron, entering one of the largest world cosmetic markets with a unique, patented product. This milestone emphasizes our strategy of serving all of our customer needs in the areas of aesthetic medicine with safe and effective breakthrough products."</p>
<p/>
<p>In the Southeast Asian countries of <span class="xn-location">Singapore</span>, <span class="xn-location">Malaysia</span> and <span class="xn-location">Indonesia</span>, elure will be marketed by Elure <span class="xn-location">Singapore</span> Pte. Ltd.</p>
<pre>
    

    For more information about elure, visit www.elureskin.com.

    About Syneron Medical Ltd.
    
</pre>
<p>Syneron Medical Ltd. - a company devoted to real technology, real science and real results - is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. With its innovative approach to aesthetic treatments, Syneron has now entered into one of the largest in-demand applications, skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in <span class="xn-location">Israel</span>. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in <span class="xn-location">North America</span>, <span class="xn-location">France</span>, <span class="xn-location">Germany</span>, <span class="xn-location">Italy</span>, <span class="xn-location">Portugal</span>, <span class="xn-location">Spain</span>, UK, <span class="xn-location">Australia</span>, <span class="xn-location">China</span>, <span class="xn-location">Japan</span>, and <span class="xn-location">Hong Kong</span> and distributors worldwide.</p>
<pre>
    

    Additional information can be found at www.syneron.com.

    SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
    
</pre>
<p>Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time.  If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.</p>
<p/>
<p>In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change.  However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.</p>
<p/>
<p> </p>
<p> </p>
<p> </p>
<pre>
    
    Contact:
    Tom Albright
    President and General Manager
    Topical Aesthetic Division, Syneron Medical Ltd.
    Office: 949-716-6670 (Extension 235)
    Cell: 949-632-9226
    [email protected]
    
</pre>
<p> </p>
<pre>
    
    Jane W. Smith
    Director of Marketing Communications
    Candela Corporation
    Office: 508-358-7637 (Extension 247)
    Cell: 978-314-1053
    [email protected]



    

For further information: Tom Albright, President and General Manager, Topical Aesthetic Division, Syneron Medical Ltd., [phone] Extension 235, Cell: [phone], [email protected], or Jane W. Smith, Director of Marketing Communications, Candela Corporation, [phone] Extension 247, Cell: [phone], [email protected] Web Site: http://www.syneron.com